Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology

Neurology

Volumn 86, Issue 19, 2016, Pages 1818-1826

  Simpson, David M ^a   Hallett, Mark ^b   Ashman, Eric J ^d   Comella, Cynthia L ^e   Green, Mark W ^a   Gronseth, Gary S ^f   Armstrong, Melissa J ^g   Gloss, David ^h   Potrebic, Sonja ⁱ   Jankovic, Joseph ^j   Karp, Barbara P ^c   Naumann, Markus ^k   So, Yuen T ^l   Yablon, Stuart A ^m  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Human Motor Control Section   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d BRONSON METHODIST HOSPITAL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h GEISINGER HEALTH SYSTEM   (United States)

ⁱ KAISER PERMANENTE MEDICAL CENTER   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k KLINIKUM AUGSBURG   (Germany)

^l STANFORD UNIVERSITY   (United States)

^m UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; NEUROTOXIN;

ADULT DISEASE; ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CHRONIC TENSION HEADACHE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISODIC MIGRAINE; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPASTICITY; SYSTEMATIC REVIEW; TRANSFORMED MIGRAINE; HEADACHE; MUSCLE SPASTICITY; TORTICOLLIS;

BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; HEADACHE; HUMANS; MUSCLE SPASTICITY; NEUROTOXINS; TORTICOLLIS;

EID: 84978384025     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002560     Document Type: Article

References (40)

1. Simpson M, Gracies JM, Graham HK, et al; for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
2. Simpson M, Blitzer A, Brashear A, et al; for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-1706.
3. Naumann M, So Y, Argoff CE, et al; for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum toxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-1714.
4. American Academy of Neurology. Clinical Practice Guidelines Process Manual, 2004 ed. St. Paul, MN: The American Academy of Neurology; 2004. Available at: https://www.aan.com/Guidelines/Home/UnderDevelopment. Accessed August 1, 2011.
5. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial. Mov Disord 2011;26:1521-1528.
6. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-623.
7. Truong D, Comella C, Fernandez HH, Ondo WG; Dys-port Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008;14:407-414.
8. Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord 1995;10:444-449.
9. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 2011;118:233-239.
10. Saad J, Gourdeau A. A direct comparison of onabotuli-numtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol 2014;34:233-236.
11. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009;15:224-231.
12. Cillino S, Raimondi G, Guepratte N, et al. Long-term efficacy of botulinum toxin A for treatment of blepharo-spasm, hemifacial spasm, and spastic entropion: a multi-centre study using two drug-dose escalation indexes. Eye 2010;24:600-607.
13. Truong D, Gollomp S, Jankovic J, et al; Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in blepharospasm. J Neural Transm 2013;120:1345-1353.
14. Kollewe K, Mohammadi B, Köhler S, et al. Blepharo-spasm: long-term treatment with either Botox, Xeomin or Dysport. J Neural Transm 2015;122:427-431.
15. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67: 94-114.
16. Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov 2013;3.
17. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308:103-109.
18. Boyce MJ, Canning CG, Mahant N, Morris J, Latimer J, Fung VS. The Toronto Western Spasmodic Torticollis Rating Scale: reliability in neurologists and physiotherapists. Parkinsonism Relat Disord 2012;18:635-637.
19. Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinum-toxinA (Xeomin) in cervical dystonia. J Neural Transm 2013;120:1699-1707.
20. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuro-pharmacol 2012;35:208-214.
21. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
22. Pappert EJ, Germanson T; Myobloc/Neurobloc European Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008;23: 510-517.
23. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64: 6-12.
24. Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord 2015;30:206-213.
25. Rystedt A, Zetterberg L, Burman J, Nyholm D, Johansson A. A comparison of Botox 100 U/mL and Dys-port 100 U/mL using dose conversion ratio 1: 3 and 1: 1.7 in the treatment of cervical dystonia: a double-blind, randomized, crossover trial. Clin Neuropharmacol 2015;38: 170-176.
26. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-323.
27. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008;23:1353-1360.
28. Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 2015;349:84-93.
29. Delgado MR, Hirtz D, Aisen M, et al; for the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74:336-343.
30. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009;41:536-544.
31. Shaw LC, Price CI, van Wijck FM, et al; BoTULS Investigators. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke 2011;42:1371-1379.
32. Rosales RL, Kong KH, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neu-rorehabil Neural Repair 2012;26:812-821.
33. Gracies JM, Brashear A, Jech R, et al; for the International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol 2015;14:992-1001.
34. Lam K, Lau KK, So KK, et al. Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study. J Am Med Dir Assoc 2012;13:477-484.
35. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neuro-toxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80: 380-385.
36. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M; GSK1358820 Spasticity Study Group. Botu-linum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010;26:1983-1992.
37. Marciniak CM, Harvey RL, Gagnon CM, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil 2012;91:1007-1019.
38. Jahangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia 2007;62:319-322.
39. Ward AB, Wissel J, Borg J, et al; BEST Study Group. Functional goal achievement in post-stroke spasticity patients: the BOTOX Economic Spasticity Trial (BEST). J Rehabil Med 2014;46:504-513.
40. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;32: 259-265.